Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SERENA-6 and the regulatory limits of radiologic progression in modern oncology.

Breast cancer research and treatment - 8 Jul 2026

Rafii Saeed, Al-Shamsi Humaid O, Brufsky Adam

Abstract excerpt

BACKGROUND: The emergence of real-time molecular monitoring has challenged traditional oncology paradigms, where radiologic progression has historically represented the primary trigger for therapeutic intervention. The SERENA-6 clinical trial introduced a novel treatment approach by adapting therapy based on ctDNA-detected molecular progression before radiologic progression in patients with HR-positive,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Estrogen Receptor alpha

Share to ESR1 gene

Share to Mutation

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 42418030
DOI: 10.1007/s10549-026-08001-8
PMCID: PMC13346206

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SERENA-6 and the regulatory limits of radiologic progression in modern oncology.PMID 42418030Read ↗

Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancer.Semantic proximity Read ↗

ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.Semantic proximity Read ↗

Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.Semantic proximity Read ↗

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read ↗

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.Semantic proximity Read ↗

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancersSemantic proximity Read ↗

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.Semantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.Semantic proximity Read ↗

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.